Randomized trial · people
Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In these trials, weight loss on tirzepatide leveled off for most adherent people by week 72, and it leveled off later in the higher-dose arms, in younger people and in women.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 1438
- Published
- 2025
- Journal
- Clin Obes
What they tested
The team wanted to know how long it takes people on tirzepatide to reach a weight plateau, and which starting traits link to reaching it sooner or later.
How the study was done
A post hoc analysis (a look back at data after the trials ended) of two randomized trials. It covered 1438 people from SURMOUNT-1 and 259 from SURMOUNT-4 with obesity or overweight who stayed on tirzepatide and lost at least 5% of their weight by the main endpoint (week 72 in SURMOUNT-1, week 88 in SURMOUNT-4).

Model. Individual results vary.
What they found
The team counted a plateau as the point when weight moved less than 5% in a 12-week stretch and in every 12-week stretch that followed. In SURMOUNT-1, the median time to reach it was 24.3, 26.0, 36.1 and 36.1 weeks for the overweight, class I, class II and class III BMI groups, and the two highest BMI groups took significantly longer than the overweight group. At the 72-week mark, 90.2%, 88.9%, 87.6% and 87.8% of those groups had plateaued. People in the 10 and 15 mg arms, younger people and women tended to plateau later, and the SURMOUNT-4 results were similar.
What it doesn’t show
This was a post hoc analysis that included only people who stayed on treatment and lost at least 5% of their weight, so people who stopped early or lost less were left out. It shows links between starting traits and timing, not that those traits cause a later plateau.
The paper
Horn et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025.
The compound
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeksRandomized trial · people · 2025
- Tirzepatide: up to 17.5% weight loss at 52 weeks in SURMOUNT-CNRandomized trial · people · 2024
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.